Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06712823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06712823 · ClinicalTrials.gov record · last posted 2026-06-29

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

Name: An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia — clinical trial record (NCT06712823)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CALM2-CAH

StatusRecruiting

PhasePhase 2

SponsorCrinetics Pharmaceuticals Inc.

Started2025-02-25

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2024-11-27; most recent amendment 2026-06-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT06712823
Lead Sponsor	Crinetics Pharmaceuticals Inc.
Conditions	Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Enrollment	200 participants
Start Date	2025-02-25
Primary Completion	2029-07 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-29